## HUM: Humana Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.7% below STRENGTH zone (3.0-6.0%); PEG 1.06 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($237.62)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 3)

**1. Humana taps Amazon's Aaron Martin to lead insurance unit as company veteran steps down**
- Source: Fierce Healthcare | 20251216T203239 | Somewhat-Bullish | Relevance: 100%
- Humana announced that longtime executive George Renaudin, president of its insurance segment, will retire next summer. Aaron Martin, formerly of Amazon, will succeed Renaudin, initially leading Humana's Medicare Advantage business before taking over the entire insurance segment. John Barger will be promoted to president of Medicare Advantage, highlighting Humana’s focus on leveraging technology and a consumer-centric approach to healthcare.

**2. Lawsuit Alert: Investors in shares of Humana Inc. (NYSE: HUM) should contact the Shareholders Foundation**
- Source: GlobeNewswire | 20251216T185924 | Bearish | Relevance: 100%
- The Shareholders Foundation, Inc. has issued an update regarding a pending lawsuit for investors in Humana Inc. (NYSE: HUM) shares. Individuals who purchased Humana shares prior to July 2022 and still hold them are advised to contact the Foundation. The lawsuit alleges that Humana Inc. made misleading statements about "pent-up demand" for healthcare services and its impact on utilization rates and profitability.

**3. Humana Inc. stock underperforms Tuesday when compared to competitors**
- Source: MarketWatch | 20251216T163000 | Bearish | Relevance: 100%
- Humana Inc. (HUM) shares fell 6.03% to $258.16 on Tuesday, underperforming the broader market which saw the S&P 500 Index decline by 0.24% and the Dow Jones Industrial Average fall by 0.62%. This drop ended a four-day winning streak for Humana stock.

**4. Humana Brings In Amazon Healthcare Exec To Lead As Insurance Chief**
- Source: Finimize | 20251216T144907 | Somewhat-Bearish | Relevance: 100%
- Humana has appointed Aaron Martin, former Amazon healthcare VP, as its new president of Medicare Advantage, overseeing the insurance segment after the current president retires next year. This leadership change signals Humana's push for digital transformation amidst rising healthcare costs and competition, though investors remain cautious, causing a slight dip in stock despite profit targets holding steady. The move highlights the broader industry trend of insurers embracing tech-savvy leaders to modernize and manage expenses.

**5. Humana Inc. Announces Executive Changes**
- Source: TradingView — Track All Markets | 20251216T131542 | Neutral | Relevance: 100%
- Humana Inc. announced executive changes, with George Renaudin, Insurance Segment President, set to retire by Q3 2026. Aaron Martin will join as President of Medicare Advantage in January 2026 before assuming Renaudin's role, and John Barger will be promoted to President of Medicare Advantage. These changes were detailed in an SEC filing on December 16, 2025.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Jefferies | $313 | $253 | +24% |
| 2025-11-25 | Barclays | $234 | $245 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Jefferies | up | Buy |
| 2025-11-25 | Barclays | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($0.14M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.3%)
- Dodge & Cox Inc.: 9.4% (-0.1%)
- JPMORGAN CHASE & CO: 8.4% (+237.0%)
- Blackrock Inc.: 8.3% (-3.0%)
- State Street Corpora: 4.5% (-0.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.06 suggests fair value with growth premium. Balance sheet: strong liquidity (2.0x). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $31.0B |
| Beta | 0.47 |
| 52W Range | $206.87 - $315.35 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.06 |
| Forward P/E | 20.6 |
| Current P/E | 15.1 |
| YoY Growth | -26.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.9% over 5 days). Below STRENGTH zone by 2.4pp (needs >3.0% for momentum thesis). MRS_5 (-1.7%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (1.00x), long-term trend not supportive. MACD histogram positive (3.41), confirming momentum. RSI neutral at 52. OFD pattern: -MTH (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.65% (CS: 43) | Neutral |
| RSI_14 | 51.8 | Neutral |
| MACD Histogram | 3.41 | Bullish |
| vs SMA20 | 1.042x | Above |
| vs SMA50 | 0.984x | Below |
| vs SMA200 | 0.998x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $258.12
- **Stop Loss:** $237.62 (7.9% risk)
- **Target:** $278.62 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 48
- **Position Value:** $12,389.76
- **Portfolio %:** 12.39%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-11 (Est: $-3.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.83 | $3.24 | +14.6% |
| 2025Q2 | $5.87 | $6.27 | +6.9% |
| 2025Q1 | $10.07 | $11.58 | +15.0% |
| 2024Q4 | $-2.12 | $-2.16 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*